Undisclosed CDK2 degrader / Plexium - LARVOL DELTA

Plexium Announces Multiple Presentations at AACR 2025 with Selective Monovalent Degrader Programs Targeting SMARCA2…and CDK2 (PRNewswire) - "Plexium...announced today multiple presentations with the Company's selective monovalent degrader programs for SMARCA2...and CDK2 at the 2025 American Association for Cancer Research (AACR) Annual Meeting....PLX-61639, a selective, oral SMARCA2 degrader, demonstrated sustained PD response and single-agent efficacy in SMARCA4 mutant tumors; program is advancing through IND-enabling studies....Preclinical data was presented on its CDK2 selective molecular glue degrader, which exhibited superior selectivity over inhibitor-based approaches; program is targeting CCNE1 amplified cancers."

Preclinical • Oncology

Discovery and characterization of novel, potent and selective CDK2 molecular glue degrader against CCNE1-amplified tumors (AACR 2025) - "Our potent and selective CDK2 molecular glue degraders provide preclinical evidence and scientific rationale for the treatment of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer, and CCNE1 amplified ovarian, gastroesophageal, and uterine cancers."

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • Uterine Cancer • CCNE1 • CDK2 • CRBN • HER-2

Plexium Announces Two Oral Presentations and Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (PRNewswire) - "Plexium...announced that initial Phase 1 clinical results with PLX-4545, a selective IKZF2 molecular glue degrader, and preclinical results from the Company's SMARCA2 monovalent direct degrader and CDK2 molecular glue degrader programs will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting..."

P1 data • Preclinical • Oncology

Discovery of potent and selective bivalent CDK2 degraders that demonstrate activity in CCNE1amp driven tumors (AACR 2024) - "These data provide validation for CDK2 degradation as a therapeutic approach. Potent and selective CDK2 bivalent degraders were exploited as tools for studying the sensitivity of CCNE1 amplified tumor models to CDK2 degradation and dependence on E3 ligase. This proof-of concept study supports Plexium's current approach of discovering novel CDK2 molecular glue degraders for the treatment of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer, and CCNE1 amplified ovarian and endometrial cancers."

Breast Cancer • Endometrial Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • CCNA2 • CCNE1 • CDK2 • CRBN • HER-2